Amarin Corporation (AMRN) Announces Results from Phase 3 MARINE, ANCHOR Study will be Presented at American Heart Association's Scientific Sessions 2011

Amarin Corporation plc (Nasdaq: AMRN) announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla. The presentation of the ANCHOR trial results will be the first presentation of data from this trial at a scientific session. The presentation of MARINE trial results will include data that has not been previously presented.

The additional MARINE data will be an oral presentation titled "Effects of AMR101, a Pure Ethyl Eicosapentaenoic Acid Omega-3 Fatty Acid, on Lipoprotein Particle Concentration and Size in Patients with Very High Triglycerides (the MARINE Study)" by Harold Bays, M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center, and principal investigator of the study. This abstract is scheduled to be presented on Tuesday, November 15, 2011 at 4:45 pm ET. The presentation will be part of a scientific session titled "New Frontiers in Lipid Management."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lumen Technologies (LUMN) to cut 7% staff
• Ciena (CIEN) Announces Retirement of Principal Accounting Officer Andrew C. Petrik
• Delta Air Lines (DAL) President Glen W. Hauenstein sells 100,000 shares in open market